IBD serological panels: Facts and perspectivesPeyrin‐Biroulet, Laurent MD1; Standaert‐Vitse, Annie PhD2; Branche, Julien MD1; Chamaillard, Mathias PhD1Inflammatory Bowel Diseases: December 2007 - Volume 13 - Issue 12 - p 1561–1566 doi: 10.1002/ibd.20226 Clinical Review: IBD Serological Panels Abstract Author Information Abstract: Beyond a defective innate immune response in inflammatory bowel disease (IBD), an increased immunological response toward microbial and self antigens has been intrinsically linked to the pathogenesis of such common immunopathologies of the gut. Mounting evidence indicates that increased seroreactivity toward certain antigens are a predictive and quantitative heritable trait, including the anti‐Saccharomyces cerevisiae antibody (ASCA). Consistently, Candida albicans and Crohn's disease‐associated NOD2 mutations have been recently identified as immunogen and genetic determinants for ASCA, respectively. In clinical practice, current panels of serological markers are not recommended for diagnosis, stratifying, and monitoring IBD. Therefore, prospective studies and highly sensitive serological panels of markers are eagerly awaited before guiding clinical decisions. Better understanding of the serological response in IBD might also provide new insights into their epidemiology and pathophysiology. (Inflamm Bowel Dis 2007) 1INSERM, U795, Lille, F‐59037, France 2INSERM, U799, Lille, F‐59037, France Email: email@example.com Received 6 June 2007; Accepted 8 June 2007 Published online 16 July 2007 in Wiley InterScience (www.interscience.wiley.com). Grant sponsor: Association Francois Aupetit; Grant sponsor: IOIBD; Grant sponsor: IRMAD; Grant sponsor: UCB Pharma; Grant sponsor: Sanofi‐Aventis. © Crohn's & Colitis Foundation of America, Inc.